Productivity Optimization And Process Calculations For AAV Affinity Chromatography

By Alejandro Becerra-Arteaga, Ph.D. and Jett Appel, Thermo Fisher Scientific, Bedford, MA, USA

Discover the key to maximizing gene therapy productivity with recombinant adeno-associated virus (rAAV) as a delivery method. This study delves into the manufacturing process, specifically the purification of rAAV using affinity capture chromatography. In this work, dynamic binding capacity (DBC) data for multiple AAV serotypes were leveraged to estimate the optimal productivity of rAAV using the AAVX resin.

The results show the relatively high binding capacity of POROS CaptureSelect AAVX resin was confirmed to be >1E15 capsids/mL resin at residence times >= 0.5 min for AAV2. Find out more about the methodology used in this study along with further results involving productivity and resin utilization.